Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII

What Was Tested

Researchers studied Goserelin in this randomized controlled trial publication.

The purpose of this article is to compare quality of life (QOL) and menopausal symptoms among premenopausal patients with lymph node-negative breast cancer receiving chemotherapy, goserelin, or their sequential combination, and to investigate differential effects by age.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, women only.

The researchers evaluated QOL data from 874 pre- and perimenopausal women with lymph node-negative breast cancer who were randomly assigned to receive six courses of classical cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy, ovarian suppression with goserelin for 24 months, or six courses of classical CMF followed by 18 months of goserelin.

The researchers report QOL data collected during 3 years after random assignment in patients without disease recurrence.

How the Study Was Run

The design is described as randomized.

Because people in this Goserelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The timeline in the abstract includes 24 months.

What Was Measured

The subject headings attached to it are Age Factors, Amenorrhea, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant and Cyclophosphamide.

What This Means in Plain Language

The paper is a randomized study of Goserelin over 24 months.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2007 (Journal of clinical oncology : official journal of the American Society of Clinical Oncology), a journal based in United States.

More context: the Goserelin compound page, all human trials.